Cyclin G2, a novel target of sulindac to inhibit cell cycle progression in colorectal cancer
Sulindac has shown significant clinical benefit in preventing colorectal cancer progression, but its mechanism of action has not been fully elucidated. We have found that sulindac sulfide (SS) is able to inhibit cell cycle progression in human colorectal cancer cells, particularly through G1 arrest....
Main Authors: | Hongyou Zhao, Bin Yi, Zhipin Liang, Ches’Nique Phillips, Hui-Yi Lin, Adam I. Riker, Yaguang Xi |
---|---|
Format: | Article |
Language: | English |
Published: |
KeAi Communications Co., Ltd.
2021-05-01
|
Series: | Genes and Diseases |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2352304220301379 |
Similar Items
-
Sulindac plus a phospholipid is effective for polyp reduction and safer than sulindac alone in a mouse model of colorectal cancer development
by: Jennifer S. Davis, et al.
Published: (2020-09-01) -
Identification of the Effects of Aspirin and Sulindac Sulfide on the Inhibition of HMGA2-Mediated Oncogenic Capacities in Colorectal Cancer
by: Titus Ime Ekanem, et al.
Published: (2020-08-01) -
Synthesis and Preliminary Screening of the Biological Activity of Sulindac Sulfoximine Derivatives
by: Cosimo Cardellicchio, et al.
Published: (2023-11-01) -
Effects of betamethasone, sulindac and quinacrine drugs on the inflammatory neoangiogenesis response induced by polyurethane sponge implanted in mouse
by: JULIO ILLANES, et al.
Published: (2002-01-01) -
Analysis of Aceclofenac, Ketorolac, and Sulindac in Human Urine Using the Microemulsion Electrokinetic Chromatography Method
by: Dadan Hermawan, et al.
Published: (2024-09-01)